Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Infectious disease & vaccines in transplantation and cellular therapy

Jose F. Camargo • 5 Feb 2021
TCT 2021
General Letermovir

Jose F. Camargo, MD, University of Miami, Miller School of Medicine, Miami, FL, provides an update in emergent topics in infectious disease and vaccines in patients undergoing hematopoietic cell transplantation and treatment with cellular therapies, including outcomes of transplant patients with COVID-19, as well as the role of the microbiome on the outcomes of patients undergoing transplant. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Jose F. Camargo

2:56
Clinical presentation & outcomes of COVID-19 following HCT
Jose F. Camargo • 5 Feb 2021

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals